Pre-market hot trades in US stocks: Scribe Therapeutics up 7.95% in pre-market; Marvell Tech up 4.88% in pre-market

On July 27, Nuwellis reported a preliminary revenue growth of 14% for the second quarter of 2026, significantly boosting the stock price. The company also expects a 20% year-over-year revenue growth in the first half of 2026, mainly due to the commercial success of the Aquadex ultrafiltration platform. Following this announcement, the market became optimistic about the company's future growth prospects, leading to a substantial pre-market stock price increase.

On July 30, Nuwellis announced that its new anticoagulation strategy study regarding the Aquadex ultrafiltration therapy was accepted by Frontiers in Pediatrics. This recognition further enhances market confidence in the company's technology, supporting the stock price increase.

On July 27, Nuwellis's preliminary financial results showed a 20% revenue growth in the first half of 2026, further solidifying investor confidence in the company's growth potential, driving the stock price up. The medical device industry is experiencing strong growth, and the market is optimistic T3 Defense pre-market rose 76.22%. Based on recent key news:

On July 29, T3 Defense rose 81.56% during the day, currently reported at $23.785. This sharp rise was mainly driven by both technical and fundamental factors. The company's completed 1-for-125 reverse stock split compressed the float to 1.12 million shares, triggering a technical short squeeze. At the same time, the company made operational progress and achieved contract delivery in the anti-drone technology field with its Project 35. X S.E. Security and Defense Ltd. acquired 16.67% equity in the company in exchange for rights to Project 35, further boosting market confidence with the strategic investment news.

On July 30, T3 Defense's stock price increased by 88%, currently reported at $45.12. The stock exhibits characteristics of "low float + high trading volume," making it prone to significant volatility.

On July 28, T3 Defense's subsidiary Industrial Techno-Logic Solutions completed the delivery of an automated composite production line to a major Israeli manufacturer, with a contract amount of $1.1 million. At the same time, the company holds 60% of Project 35, further expanding its influence in the high-demand anti-drone technology field. SEC Schedule 13D filings show that X S.E. Security and Defense Ltd. acquired 16.67% of T3 Defense's common stock, further enhancing investor interest. Recently, there has been strong demand in the defense industry, with significant capital inflow.

SCTX